Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
RemeGen Co. Ltd. Class H ( (HK:9995) ) has provided an update.
RemeGen has obtained approval from China’s National Medical Products Administration for a new indication of its flagship drug Disitamab Vedotin to treat adult patients with unresectable or metastatic HER2-low breast cancer with liver metastases who have previously received systemic therapy. The decision, based on positive Phase III trial results in China, marks the fourth approved indication for the ADC, expanding its clinical use from gastric and urothelial cancers and HER2-positive breast cancer to a broader HER2-low breast cancer population with significant unmet medical need.
The new approval strengthens Disitamab Vedotin’s competitive position in China’s oncology market and underscores RemeGen’s role in advancing targeted therapies for difficult-to-treat breast cancer subsets. While the company highlights the potential commercial benefits, it also cautions that actual market performance will depend on policy conditions, demand, and competitive dynamics, introducing uncertainties for shareholders and prospective investors.
The most recent analyst rating on (HK:9995) stock is a Hold with a HK$82.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.
More about RemeGen Co. Ltd. Class H
RemeGen Co., Ltd. is a biopharmaceutical company based in China that focuses on developing innovative antibody-drug conjugates and other targeted cancer therapies. Its lead product, Disitamab Vedotin, is an original HER2-targeting ADC aimed at treating multiple solid tumors, including gastric, urothelial, and various forms of breast cancer in the Chinese market.
Average Trading Volume: 4,006,250
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$66.25B
Find detailed analytics on 9995 stock on TipRanks’ Stock Analysis page.